Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 18.35 USD 7.06% Market Closed
Market Cap: 616.6m USD
Have any thoughts about
Grail Inc?
Write Note

Grail Inc
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Grail Inc
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
Common Shares Outstanding
$26.6m
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Common Shares Outstanding
$1.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Common Shares Outstanding
$1.2B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Common Shares Outstanding
$537.5m
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Common Shares Outstanding
$257.7m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Common Shares Outstanding
$110.1m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
No Stocks Found

Grail Inc
Glance View

Market Cap
609.3m USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
19.1 USD
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Grail Inc's Common Shares Outstanding?
Common Shares Outstanding
26.6m USD

Based on the financial report for Dec 31, 2023, Grail Inc's Common Shares Outstanding amounts to 26.6m USD.

What is Grail Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
-42%

Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for Grail Inc have been -42% over the past three years .

Back to Top